New cholesterol guidelines and primary prevention in women

Trends in Cardiovascular Medicine

Volumn 25, Issue 2, 2015, Pages 84-94

  Gulati, Martha ^a   Noel Bairey Merz, C ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; MYOPATHY; NEOPLASM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; UNITED STATES; WOMEN'S HEALTH; ADULT; ATHEROSCLEROSIS; BLOOD; FEMALE; PRIMARY PREVENTION; PROCEDURES;

ADULT; ATHEROSCLEROSIS; CHOLESTEROL; FEMALE; GUIDELINES AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; RISK FACTORS;

EID: 84923035968     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.08.007     Document Type: Review

References (44)

1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
2. Gupta A., Wang Y., Spertus J.A., Geda M., Lorenze N., Nkonde-Price C., et al. Trends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010. J Am Coll Cardiol 2014, 64:337-345.
3. Lloyd-Jones D.M., Hong Y., Labarthe D., Mozaffarian D., Appel L.J., Van Horn L., et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the american heart association's strategic impact goal through 2020 and beyond. Circulation 2010, 121:586-613.
4. Yang Q., Cogswell M.E., Flanders W.D., Hong Y., Zhang Z., Loustalot F., et al. Trends in cardiovascular health metrics and associations with all-cause and cvd mortality among us adults. J Am Med Assoc 2012, 307:1273-1283.
5. Berry J.D., Dyer A., Cai X., Garside D.B., Ning H., Thomas A., et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012, 366:321-329.
6. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014, 129:S1-S45.
7. Goff D.C., Lloyd-Jones D.M., Bennett G., Coady S., D'Agostino R.B., Gibbons R., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014, 129:S49-S73.
8. The aric investigators. Am J Epidemiol 1989, 129:687-702. The Atherosclerosis Risk in Communities (Aric) Study: Design and Objectives.
9. Fried L.P., Borhani N.O., Enright P., Furberg C.D., Gardin J.M., Kronmal R.A., et al. The cardiovascular health study: design and rationale. Ann Epidemiol 1991, 1:263-276.
10. Friedman G.D., Cutter G.R., Donahue R.P., Hughes G.H., Hulley S.B., Jacobs D.R., et al. Cardia: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988, 41:1105-1116.
11. Dawber T.R., Kannel W.B., Lyell L.P. An approach to longitudinal studies in a community: the Framingham study. Ann N Y Acad Sci 1963, 107:539-556.
12. Kannel W.B., Feinleib M., McNamara P.M., Garrison R.J., Castelli W.P. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979, 110:281-290.
13. Muntner P., Colantonio L.D., Cushman M., Goff D.C., Howard G., Howard V.J., et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. J Am Med Assoc 2014, 311:1406-1415.
14. Ray K.K., Kastelein J.J., Boekholdt S.M., Nicholls S.J., Khaw K.T., Ballantyne C.M., et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014, 35:960-968.
15. Ridker P.M., Cook N.R. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013, 382:1762-1765.
16. Pencina M.J., Navar-Boggan A.M., D'Agostino R.B., Williams K., Neely B., Sniderman A.D., et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014, 370:1422-1431.
17. Kavousi M., Leening M.J., Nanchen D., Greenland P., Graham I.M., Steyerberg E.W., et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. J Am Med Assoc 2014, 311:1416-1423.
18. Paixao A.R., Ayers C.R., Berry J.D., de Lemos J.A., Khera A. Atherosclerotic cardiovascular disease prevention: a comparison between the third adult treatment panel and the new 2013 treatment of blood cholesterol guidelines. Circulation 2014, Available at: http://circoutcomes.ahajournals.org/content/early/2014/08/05/CIRCOUTCOMES.114.001139.citation.
19. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
20. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
21. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
22. Walsh J.M., Pignone M. Drug treatment of hyperlipidemia in women. J Am Med Assoc 2004, 291:2243-2252.
23. Abramson J.D., Redberg R.F. Don't give more patients statins. The New York Times 2013, Available at: http://www.nytimes.com/2013/11/14/opinion/dont-give-more-patients-statins.html?_r=0. Accessed July 30, 2014.
24. Dale K.M., Coleman C.I., Shah S.A., Patel A.A., Kluger J., White C.M. Impact of gender on statin efficacy. Curr Med Res Opin 2007, 23:565-574.
25. Ray K.K., Seshasai S.R., Erqou S., Sever P., Jukema J.W., Ford I., et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010, 170:1024-1031.
26. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
27. Bukkapatnam R.N., Gabler N.B., Lewis W.R. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol 2010, 13:84-90.
28. Mora S., Glynn R.J., Hsia J., MacFadyen J.G., Genest J., Ridker P.M. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010, 121:1069-1077.
29. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Am Med Assoc 2002, 288:2998-3007.
30. Desai C.S., Martin S.S., Blumenthal R.S. Non-cardiovascular effects associated with statins. Br Med J 2014, 349:g3743.
31. McDougall J.A., Malone K.E., Daling J.R., Cushing-Haugen K.L., Porter P.L., Li C.I. Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age. Cancer Epidemiol Biomarkers Prev 2013, 22:1529-1537.
32. Desai P., Chlebowski R., Cauley J.A., Manson J.E., Wu C., Martin L.W., et al. Prospective analysis of association between statin use and breast cancer risk in the women's health initiative. Cancer Epidemiol Biomarkers Prev 2013, 22:1868-1876.
33. Cauley J.A., McTiernan A., Rodabough R.J., LaCroix A., Bauer D.C., Margolis K.L., et al. Statin use and breast cancer: prospective results from the women's health initiative. J Natl Cancer Inst 2006, 98:700-707.
34. Cauley J.A., Zmuda J.M., Lui L.Y., Hillier T.A., Ness R.B., Stone K.L., et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Women's Health 2003, 12:749-756.
35. Kwan M.L., Habel L.A., Flick E.D., Quesenberry C.P., Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 2008, 109:573-579.
36. Woditschka S., Habel L.A., Udaltsova N., Friedman G.D., Sieh W. Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 2010, 19:2479-2487.
37. Ahern T.P., Pedersen L., Tarp M., Cronin-Fenton D.P., Garne J.P., Silliman R.A., et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 2011, 103:1461-1468.
38. Mihaylova B., Emberson J., Blackwell L., Keech A., Simes J., Barnes E.H., et al. The effects of lowering ldl cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
39. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
40. Culver A.L., Ockene I.S., Balasubramanian R., Olendzki B.C., Sepavich D.M., Wactawski-Wende J., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch Intern Med 2012, 172:144-152.
41. Wing R.R., Bolin P., Brancati F.L., Bray G.A., Clark J.M., Coday M., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154.
42. Eckel R.H., Jakicic J.M., Ard J.D., de Jesus J.M., Houston Miller N., Hubbard V.S., et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College Of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014, 129:S76-S99.
43. Jensen M.D., Ryan D.H., Apovian C.M., Ard J.D., Comuzzie A.G., Donato K.A., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College Of Cardiology/American Heart Association Task Force on practice guidelines and the obesity society. Circulation 2014, 129:S102-S138.
44. Goodarzi M.O., Li X., Krauss R.M., Rotter J.I., Chen Y.D. Relationship of sex to diabetes risk in statin trials. Diabetes Care 2013, 36:e100-e101.